Review
Oncology
Claudia Mosillo, Maria Letizia Calandrella, Claudia Caserta, Serena Macrini, Annalisa Guida, Grazia Sirgiovanni, Sergio Bracarda
Summary: This review summarizes and discusses new therapeutic approaches for metastatic castration-resistant prostate cancer, including the prognostic and predictive role of molecular alterations, investigation techniques, and potential clinical implications. Despite the approval of several drugs, metastatic castration-resistant prostate cancer remains a lethal disease.
Article
Oncology
Maria Massaro, Giuseppe Facondo, Gianluca Vullo, Anna Maria Aschelter, Alessandro Rossi, Vitaliana De Sanctis, Paolo Marchetti, Mattia Falchetto Osti, Maurizio Valeriani
Summary: This study aimed to investigate the efficacy of radiotherapy as metastasis-directed therapy in metastatic castration-resistant prostate cancer patients, and found that radiotherapy has a positive impact on prolonging the clinical benefit of ARTT.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jun Li, Nan Liu, Hong Zhou, Peng Xian, Yanping Song, Xianli Tang, Yuan Li, Michael Basler
Summary: This study found that immunoproteasome inhibition has a significant effect on suppressing the progression of castration-resistant prostate cancer (CRPC). The results showed that immunoproteasome inhibition prevents CRPC progression by suppressing inflammation and inducing apoptosis of CRPC cells through activating the unfolded protein response.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Asta Juzeniene, Vilde Yuli Stenberg, Oyvind Sverre Bruland, Roy Hartvig Larsen
Summary: There is currently no cure for late stage metastatic prostate cancer, but targeted alpha therapy focusing on the overexpressed protein PSMA may offer a promising treatment option. This therapy utilizes radionuclides emitting alpha-particles to target PSMA, potentially providing a more effective and selective treatment option for patients.
Article
Chemistry, Physical
Pengyuan Liu, Yajun Wu, Xiaogang Xu, Xudong Fan, Chuan Sun, Xiaojie Chen, Jindan Xia, Shiting Bai, Li Qu, Huasong Lu, Jing Wu, Jun Chen, Ji-Gang Piao, Zhibing Wu
Summary: A novel nanotechnology-based strategy combining microwaves and photothermal therapy has been developed for the precise target treatment of castration-resistant prostate cancer (CRPC). The nanoplatform achieves accurate drug delivery, precise ablation, and controlled release of the chemotherapeutic agent doxorubicin (DOX) under near-infrared (NIR) irradiation, providing an accurate, controllable, efficient, non-invasive, and safe treatment platform for targeting CRPC.
Review
Oncology
Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Christelle Fargette, Michael Baboudjian, Laurence Colleaux, David Taieb, Palma Rocchi
Summary: Castration-resistant prostate cancer remains a significant medical challenge, and it is important to understand the underlying mechanisms of resistance and develop new treatment approaches. This review provides an overview of the mechanisms contributing to CRPC progression and discusses current treatment options.
Article
Oncology
Julius Semenas, Tianyan Wang, Azharuddin Sajid Syed Khaja, A. K. M. Firoj Mahmud, Athanasios Simoulis, Thomas Grundstrom, Maria Fallman, Jenny L. Persson
Summary: Tamoxifen shows good tolerance in heavily pretreated castration-resistant prostate cancer patients. It exerts inhibitory effects by targeting cyclin D1 and PIP5K1 alpha/AKT network in prostate cancer cells, and can achieve superior inhibition when used in combination with other inhibitors such as ISA-2011B.
MOLECULAR ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Article
Cell Biology
Tianyan Wang, Martuza Sarwar, Jonathan B. Whitchurch, Hilary M. Collins, Tami Green, Julius Semenas, Amjad Ali, Christopher J. Roberts, Ryan D. Morris, Madlen Hubert, Sa Chen, Zahra El-Schich, Anette G. Wingren, Thomas Grundstroem, Richard Lundmark, Nigel P. Mongan, Lena Gunhaga, David M. Heery, Jenny L. Persson
Summary: This study identifies the role of PIP5K1α in promoting the growth and invasion of castration-resistant prostate cancer. The study also reveals the importance of the N-terminal domain of PIP5K1α and its function as an upstream regulator of androgen receptor and its target genes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Bo-Ren Wang, Yu-An Chen, Wei-Hsiang Kao, Chih-Ho Lai, Ho Lin, Jer-Tsong Hsieh
Summary: Prostate cancer is a common cancer among men, and a significant percentage of patients develop metastatic prostate cancer. Treating castration-resistant prostate cancer (CRPC) is challenging, but recent research has identified new anti-androgen agents and targeting drugs that can prolong the survival of CRPC patients.
Article
Oncology
Junjiang Liu, Yunxia Zhang, Shoubin Li, Fuzhen Sun, Gang Wang, Dong Wei, Tao Yang, Shouyi Gu
Summary: Androgen deprivation therapy (ADT) can increase the expression of androgen receptor (AR) through amplification of chromosome X in prostate cancer. The overexpression of OPHN1, which is located in the same region as the AR gene, was found to promote cell survival, inhibit apoptosis, and enhance resistance to ADT, thereby facilitating prostate cancer progression.
Article
Oncology
Caroline Burgard, Florian Rosar, Robert J. Marlowe, Mark Bartholomae, Sebastian Dewes, Andrea Schaefer-Schuler, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin
Summary: The tumor sink effect, which leads to decreased uptake of radiopharmaceuticals in healthy organs due to their sequestration by tumors, may impact the toxicity and dosing of radioligand therapy (RLT). In this study, we investigated the tumor sink effects of prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals in the organs-at-risk of 33 patients with metastatic castration-resistant prostate cancer (mCRPC). Our findings suggest the presence of tumor sink effects in the salivary glands and spleen, and possibly the liver, and support the use of individualized RLT dosing based on changes in tumor burden to improve efficacy/toxicity ratio.
Article
Biochemistry & Molecular Biology
Yong Luo, Xiaobing Yang, Spyridon P. Basourakos, Xuemei Zuo, Dechao Wei, Jiahui Zhao, Mingchuan Li, Qiankun Li, Tao Feng, Pengju Guo, Yongguang Jiang
Summary: Previous studies have shown that upregulation of CXCR7 expression is associated with increased invasion, migration, and angiogenesis in CRPC cells. In this study, inhibition of CXCR7 with a specific inhibitor led to reduced levels of p-JAK2, p-STAT1, C-Myc, and VEGFR2. Targeting JAK2/STAT1 signaling pathway resulted in enhanced apoptosis, reduced migration, and decreased tumor growth in CRPC xenografts. Combination therapy targeting both AR and JAK2/STAT1 showed substantial tumor suppression by decreasing DNA damage repair and increasing apoptosis.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thorsten Derlin, Liam Widjaja, Rudolf A. Werner, Frank M. Bengel
Summary: The study aimed to evaluate the feasibility, additional benefit, and toxicity of extending prostate-specific membrane antigen (PSMA) targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. The results showed that extending the treatment could achieve additional therapeutic effect with mild toxicity. Therefore, treatment extension is feasible and effective for patients with metastatic castration-resistant prostate cancer.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Oncology
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjostrom, Shuang G. Zhao
Summary: In this study, the researchers identified the intrinsic molecular subtypes of metastatic castration-resistant prostate cancer (mCRPC) and assessed their molecular and clinical correlates using a large cohort with gene expression data. The results showed the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, emphasizing the need for transcriptome-wide profiling in future studies to understand the impact of these differences on treatment responses and outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Cell Biology
Zhenhua Chen, Jiaxing Zhang, Zhiling Zhang, Zihao Feng, Jinhuan Wei, Jun Lu, Yong Fang, Yanping Liang, Junjie Cen, Yihui Pan, Yong Huang, Fangjian Zhou, Wei Chen, Junhang Luo
CELL DEATH & DISEASE
(2017)
Article
Oncology
Yong Huang, Jinhuan Wei, Yong Fang, Zhenhua Chen, Junjie Cen, Zihao Feng, Jun Lu, Yanping Liang, Junhang Luo, Wei Chen
CANCER MANAGEMENT AND RESEARCH
(2018)
Article
Oncology
Yong Huang, Junjie Cen, Jinhuan Wei, Zhenhua Chen, Yong Fang, Zihao Feng, Jun Lu, Yanping Liang, Junhang Luo, Chengqiang Mo, Wei Chen
Article
Oncology
Yong Fang, Jun-Jie Cen, Jia-Zheng Cao, Yong Huang, Zi-Hao Feng, Jun Lu, Jin-Huan Wei, Zhen-Hua Chen, Yan-Ping Liang, Bing Liao, Jun-Hang Luo, Wei Chen
Article
Cell Biology
Ji-Ming Bao, Qiang Dang, Chun-Jung Lin, U-Ging Lo, Boris Feldkoren, Andrew Dang, Elizabeth Hernandez, Fei Li, Vandana Panwar, Cheng-Fan Lee, Jun-Jie Cen, Bing Guan, Vitaly Margulis, Payal Kapur, Rolf A. Brekken, Jun-Hang Luo, Jer-Tsong Hsieh, Wan-Long Tan
Summary: The aberrant expression of TGF-beta 1 is associated with RCC progression, with SPARC identified as a critical effector in the TGF-beta signaling pathway. Elevated SPARC expression in RCC is positively correlated with disease stage and grade, while inversely correlated with patient survival. Targeting SPARC may be a potential therapeutic strategy for RCC metastasis.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Dermatology
Deng Zhang, Junjie Cen, Pengju Li, Li Shao, Jinhuan Wei, Zhenhua Chen, Junhang Luo, Wei Chen, Yong Huang
WOUND MANAGEMENT & PREVENTION
(2020)
Article
Biochemistry & Molecular Biology
Junjie Cen, Yanping Liang, Yong Huang, Yihui Pan, Guannan Shu, Zhousan Zheng, Xiaozhong Liao, Mi Zhou, Danlei Chen, Yong Fang, Wei Chen, Junhang Luo, Jiaxing Zhang
Summary: CircSDHC expression is correlated with advanced TNM stage and poor survival in RCC patients, and it promotes RCC progression by competitively binding to miR-127-3p, thereby preventing its suppression of CDKN3 and the E2F1 pathway. This suggests that circSDHC could be a potential therapeutic target in RCC treatment.
Article
Oncology
Lei Tan, Yiming Tang, Hongbo Li, Pengju Li, Yunlin Ye, Junjie Cen, Chengpeng Gui, Junhang Luo, Jiazheng Cao, Jinhuan Wei
Summary: This study characterized a lncRNA DUXAP9 in localized ccRCC and found that high expression of DUXAP9 is associated with poor prognosis. Knockdown of DUXAP9 inhibited renal cancer cell proliferation and motility, while overexpression promoted these capacities. DUXAP9 may serve as a prognostic marker and therapeutic target in localized ccRCC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Urology & Nephrology
Jun Lu, Junjie Cen, Wenwei Wang, Hongwei Zhao, Pengju Li, Jiacong Mo, Zhenhua Chen, Yiming Tang, Jinhuan Wei, Junhang Luo, Shiying Huang, Yong Fang
Summary: Positioning the external urethral orifice in the coronary sulcus may help reduce the occurrence of epididymitis for patients with hypospadias complicating with a PUC connecting to the vas deferens.
Article
Chemistry, Multidisciplinary
Mi Zhou, Jiaqi Dong, Junqing Huang, Wen Ye, Zhousan Zheng, Kangbo Huang, Yihui Pan, Junjie Cen, Yanping Liang, Guannan Shu, Sheng Ye, Xuanxuan Lu, Jiaxing Zhang
Summary: Chemoresistance is a major challenge in gastric cancer treatment. This study identifies a novel lncRNA TMEM44-AS1 related to 5-FU resistance and develops a new nanocarrier CGE for efficient delivery of si-TMEM44-AS1, leading to the reversal of 5-FU resistance and enhanced therapeutic effect in a mouse model.
Letter
Urology & Nephrology
Wanmei Zhong, Junjie Cen, Yu Chen, Wei Chen, Junhang Luo, Xu Chen
ASIAN JOURNAL OF UROLOGY
(2021)
Article
Oncology
Yong Huang, Junjie Cen, Zhuowei Liu, Jinhuan Wei, Zhenhua Chen, Zihao Feng, Jun Lu, Yong Fang, Fangjian Zhou, Junhang Luo, Chengqiang Mo, Wei Chen
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2019)
Article
Urology & Nephrology
U-Ging Lo, Jiming Bao, Junjie Cen, Hsin-Chih Yeh, Junhang Luo, Wanlong Tan, Jer-Tsong Hsieh
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY
(2019)
Article
Oncology
Zi-Hao Feng, Yong Fang, Liang-Yun Zhao, Jun Lu, Yong-Qian Wang, Zhen-Hua Chen, Yong Huang, Jin-Huan Wei, Yan-Ping Liang, Jun-Jie Cen, Yi-Hui Pan, Bing Liao, Wei Chen, Jun-Hang Luo